Interview with Sergio Duplan, CPO Head & Country President Mexico, Novartis…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Address: Calzada de Tlalpan #1779, Colonia San Diego Churubusco, Mexico D.F.,Mexico
Tel: (55) 5420-8600
Web: http://www.novartis.com.mx/10ybrand/NOVARTIS_WEB_2009/Soft_Templates/index.html
In Mexico, the Novartis Group consists of Novartis Pharmaceuticals, Sandoz, OTC, CIBA Vision, Novartis Animal Health, and Novartis Vaccines and Diagnostics. More than 1,700 employees and more than $7 billion MXP sales revenue in 2011.
Novartis Pharmaceuticals (patented medicines), Sandoz (generic products), OTC (prescription free medicines), CIBA Vision (provider of high technology contact lenses and their care products), Novartis Animal Health (health care for pets and livestock) and Novartis Vaccines and Diagnostics (vaccines and clinical diagnostic products).
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Eric Alvarez, managing director of Janssen Mexico, explains why it is important to distinguish between the public and private sector when discussing the latest developments in the pharmaceutical industry, and…
Teleflex is committed to solving the challenges of a changing healthcare environment in the areas of critical care and surgical applications by providing every day new products. The managing director…
Internationalization and innovation are part of Chiesi’s history. The general manager of the recently started Mexican affiliate discusses the company’s priorities for the second largest market in Latin America and…
Cecilia Calderón shares her experience as founder and general manager of Vigpharma, her perspectives on the pharmacovigilance and technovigilance in Mexico and the main challenges that come with being the…
The director of Bacher Zoppi reveals how the Mexican pharma sector is back in the spotlight of the international investor community, explains how the distribution environment has evolved with power…
The corporate development director and business development manager of UpPharma explain why Market Expansion Services (MES) model represents a unique business opportunity for firms looking to establish themselves in the…
The councillor at the Swiss Embassy talks about how the two countries have a particularly close relationship when it comes to pharma, the challenge of introducing innovative products to the…
José Angel García Hinojosa, vice president sales and marketing of the Grupo Loeffler Russek, discusses the history of the company since its establishment until its most recent accomplishments. Always with…
Landsteiner is betting on biotech and genomics. The head of new developments and the head of genomic research share their views on the future of the company as well as…
The president and founder of Knobloch Information Group, the leading supplier of market data to the pharmaceutical industry in Mexico, provides an in-depth overlook about the most important changes that…
Innovation is a product’s added value, ensuring that the patient is ready to buy. The former director of R&D and today CEO of Carnot explains how the company is undergoing…
Pablo Escandón shares his experience as CEO of Nadro and how retail changes have transformed the Mexican market, his perspectives on the accessibility of medicine for Mexicans and the challenges…
See our Cookie Privacy Policy Here